Hutch News

Stories tagged 'Vaccine and Infectious Disease'

Good News at Fred Hutch

Celebrating faculty and staff achievements

Jan. 12, 2017

Celebrating faculty and staff achievements

View story >


New library of HIV mutants could inform vaccine design

Laboratory manipulation of the AIDS-causing virus reveals evolutionary ‘dead-ends’

Jan. 12, 2017 | By Rachel Tompa / Fred Hutch News Service

Fred Hutch researchers have created a library containing millions of mutant HIV viruses. Some of these mutants are very good at infecting human cells, no different from their “natural” viral ancestor. Some of them are worse. Together, they can teach researchers something important about HIV in humans.

View story >


'We've become full partners'

An HIV laboratory in South Africa advances scientific understanding, and more

Jan. 6, 2017 | By Mary Engel / Fred Hutch News Service

Fred Hutch immunologist Dr. Erica Andersen-Nissen moved to Cape Town, South Africa, in 2013 to set up a state-of-the-art HIV laboratory to anchor two groundbreaking vaccine clinical trials. This is the story of building that lab, from the people up.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Jan. 5, 2017

Dr. Jonathan Bricker offers 5 steps for keeping resolutions in the new year; Dr. Trevor Bedford a finalist for first-ever Open Science Prize; 425 Magazine salutes HIV researcher Dr. Larry Corey and community advocate Michael Louella

View story >


On the path to a new-generation malaria vaccine

New approach using genetically modified parasite ‘primes the immune system’ in first human trial

Jan. 4, 2017 | By Mary Engel / Fred Hutch News Service

Volunteers in a clinical trial led by Fred Hutch's Dr. Jim Kublin endured 150 to 200 mosquito bites in one 10-minute session to test a new approach to a malaria vaccine that uses genetically attenuated, or weakened, parasites to stimulate an immune response to malaria without causing disease.

View story >


Experimental herpes drug more effective than standard treatment

Pritelivir reduces viral shedding and lesions better than valacyclovir, study shows

Dec. 20, 2016 | By Mary Engel / Fred Hutch News Service

The results of the phase 2, randomized, double-blind trial published today in JAMA showed that when people with genital herpes took a daily oral dose of pritelivir, they reduced their rate of viral shedding by half compared to when they took valacyclovir. They also had fewer genital sores and less pain.

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.